Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
01 November 2023 - 1:30PM
NetworkNewsAudio –
Lexaria Bioscience Corp. (NASDAQ:
LEXX) announces the availability of a broadcast titled,
“Can Diabetes, Weight-Loss Drugs Get Even Better?”
To hear the AudioPressRelease, please visit: The
NetworkNewsAudio News Podcast
To view the full editorial, please
visit: https://nnw.fm/q9osg
It shouldn’t be surprising that analysts at Markets and Research
estimate the global diabetes drug market at $63.1 billion in 2021
on its way to $82.93 billion in 2027, while the global market for
diabetes devices was valued at another $26.1 billion and growing
7.5% annually. Due to the pain and unpleasantness of injections,
many diabetes sufferers prefer to treat their condition with drugs
rather than devices, if they have the choice. Some of the most
popular type 2 diabetes in recent years are GLP-1 (glucagon-like
peptide-1) receptor agonists. They work by mimicking the effects of
the naturally occurring hormone GLP-1, which helps to regulate
blood sugar levels and appetite.
Lexaria Bioscience Corp. (NASDAQ: LEXX) began
its DehydraTECH diabetes-related formal studies in 2022 with
compelling data highly relevant to diabetes showing positive
effects of lowering glucose levels, body weight and triglyceride
levels, as well as evidenced increased locomotor activity. With
such positive early results, Lexaria is expanding its diabetes
study program, including using DehydraTECH for GLP-1 drugs alone
and in combination with other molecules.
About Lexaria Bioscience Corp.
Lexaria’s patented drug-delivery technology, DehydraTECH(TM),
improves the way active pharmaceutical ingredients (APIs) enter the
bloodstream through oral delivery. Since 2016, DehydraTECH has
repeatedly demonstrated the ability to increase bio-absorption with
cannabinoids, antiviral drugs, PDE5 inhibitors and more.
DehydraTECH has also evidenced an ability to deliver some drugs
more effectively across the blood brain barrier. Lexaria operates a
licensed in-house research laboratory and holds a robust
intellectual property portfolio with 37 patents granted and many
patents pending worldwide.
For more information, visit the company’s website
at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and
updates relating to LEXX are available in the company’s newsroom
at https://ibn.fm/LEXX
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications
platform with a focus on financial news and content distribution
for private and public companies and the investment community. It
is one of 60+ brands within the Dynamic Brand
Portfolio @ IBN that
delivers: (1) access to a vast network of
wire solutions via InvestorWire to efficiently and
effectively reach a myriad of target markets, demographics and
diverse industries; (2) article
and editorial syndication to 5,000+
outlets; (3) press release
enhancement to ensure maximum
impact; (4) social media
distribution via IBN to millions of social media
followers; and (5) a full array of
tailored corporate communications solutions. With broad reach
and a seasoned team of contributing journalists and writers, NNW is
uniquely positioned to best serve private and public companies that
want to reach a wide audience of investors, influencers, consumers,
journalists and the general public. By cutting through the overload
of information in today’s market, NNW brings its clients
unparalleled recognition and brand awareness. NNW is where breaking
news, insightful content and actionable information converge.
For more information, please
visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or republished:
https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWireNew York, NY www.NetworkNewsWire.com 212.418.1217
Office Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
Von Sep 2023 bis Sep 2024